MannKind Corporation

Healthcare · Biotechnology · United States

Last price 3.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company’s commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult...